NZ587622A

NZ587622A - Noribogaine compositions

Info

Publication number: NZ587622A
Application number: NZ58762210A
Authority: NZ
Inventors: Robert M Moriarty
Original assignee: Demerx Inc
Priority date: 2010-07-23
Filing date: 2010-08-27
Publication date: 2012-02-24
Also published as: AU2010214685B1; AU2010214685C1

Abstract

Disclosed is a composition comprising noribogaine (as depicted) wherein at least 95 percent of the noribogaine is present as the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and further wherein said composition comprises less than 100 ppm ibogaine contamination relative to the total amount of noribogaine.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 587622 RECIEVED IPONZ 27 AUGUST 2010 NEW ZEALAND Patents Act 1953 Patents Form No. 5 COMPLETE SPECIFICATION Title: NORIBOGAINE COMPOSITIONS DemeRx, Inc., of 1234 Airport Road, Suite 105, Destin, FL 32541, United States of America (United States), do hereby declare the invention for which we pray that a patent may be granted to us and the method by which it is to be performed, to be particularly described in and by the following statement. -1- RECIEVED IPONZ 27 AUGUST 2010 2 NORIBOGAINE COMPOSITIONS Field of the Invention

[0001] This invention relates noribogaine compositions. In one embodiment, the noribogaine compositions comprise at least 95% noribogaine having the 2(R), 4(S), 5(S), 6(S) and 18(R) configuration and having less than 100 ppm ibogaine as an impurity relative to the amount of noribogaine present in the composition.

[0002] Noribogaine is a well known member of the ibogaine family of alkaloids and is sometimes referred to as 12-hydroxyibogaine. US Patent No. 2,813,873 claims noribogaine albeit as "12-O-demethylibogaine" while providing an incorrect structural formula for ibogaine. The structure of noribogaine has now been determined and found to combine the features of tyrptamine, tetrahydrohavaine and indolazepines. Noribogaine can be depicted by the following formula: where the configuration at the 2, 4, 5, 6 and 18 atoms are 2(R), 4(S), 5(S), 6(S) and 18(R).

[0003] Noribogaine and its pharmaceutically acceptable salts have recently received significant attention as a non-addictive alkaloid useful in treating drug dependency (U.S. Patent No. 6,348,456) and as a potent analgesic (U.S. Patent No. 7,220,737). Both of these patents are incorporated herein by reference in their entirety. State of the Art 7 HO

[0004] Conventionally, noribogaine is prepared by O-demethylation of naturally occurring ibogaine: RECIEVED IPONZ 27 AUGUST 2010 3 which is isolated from Tabernanth iboga, a shrub of West Africa. Demethylation may be accomplished by conventional techniques such as by reaction with boron tribromide/methylene chloride at room temperature followed by conventional purification.

[0005] Ibogaine possesses hallucinogenic properties and is a Schedule 1-controlled substance as provided by the US Food and Drug Administration. Accordingly, methods for preparing noribogaine from ibogaine require high levels of assurance that contamination with unacceptable amounts of ibogaine is avoided. However, noribogaine so prepared has not been reported as being substantially free of ibogaine (e.g., less than 100 ppm). At best, U.S. Patent No. 6,348,456 claims an essentially pure noribogaine compound but fails to disclose any methods for purification let alone what the phrase "essentially pure" encompassed or, for that matter, the level of ibogaine remaining in the composition. The synthesis of noribogaine from ibogaine was reported in U.S. Patent No. 2,813,873. However, the '873 patent was silent as to the purity of the noribogaine obtained in that synthetic process.

[0006] Accordingly, there is an ongoing need to provide a noribogaine which is enantiomeric ally enriched (greater than 95% of the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer) and essentially free of ibogaine (less than 100 ppm ibogaine relative to the amount of noribogaine). Such a total synthesis should be stereoselective as undesired stereoisomers can often lead to undesired and potentially dangerous side effects when administered to a patient. Summary of the Invention

[0007] This invention provides noribogaine compositions which are enantiomerically enriched and essentially free of ibogaine. Such compositions provide a significant breakthrough in the treatment of addiction and/or pain as the compositions will not contain unacceptable amounts of ibogaine and are enantiomerically enriched. RECIEVED IPONZ 27 AUGUST 2010 4

[0008] Accordingly, in one of its composition aspects, this invention is directed to a composition comprising noribogaine wherein at least 95% of the noribogaine is present as the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and further wherein said composition comprises less than 100 ppm ibogaine contamination relative to the total amount of noribogaine.

[0009] In some embodiments, the amount of ibogaine contained in the noribogaine compositions is less than 50 ppm, or less than 1 ppm ibogaine and preferably less than 100 ppt ibogaine.

[0010] In some embodiments, at least 98% of the noribogaine is present as the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and, preferably, at least 99%, and more preferably, at least 99.5%.

[0011] In some embodiments, the noribogaine of this invention is covalently bound to an inert solid support through a cleavable linker. Detailed Description of the Invention

[0012] This invention is directed to compositions comprising noribogaine and, in particular, compositions comprising highly pure noribogaine as the (R), 4(S), 5(S), 6(S) and 18(R) enantiomer. However, prior to describing this invention in greater detail, the following terms will first be defined.

[0013] It is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0014] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutically acceptable excipient" includes a plurality of such excipients. 1. Definitions

[0015] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention RECIEVED IPONZ 27 AUGUST 2010 5 belongs. As used herein the following terms have the following meanings.

[0016] As used herein, the term "comprising" or "comprises" is intended to mean that the compositions and methods include the recited elements, but not excluding others. "Consisting essentially of' when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose. Thus, a composition consisting essentially of the elements as defined herein would not exclude other materials or steps that do not materially affect the basic and novel characteristic(s) of the claimed invention. "Consisting of' shall mean excluding more than trace elements of other ingredients and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention.

[0017] Except as it relates to the amount of noribogaine, the term "about" when used before a numerical designation, e.g., temperature, time, amount, and concentration, including range, indicates approximations which may vary by ( + ) or (-) 10 %, 5 % or 1 %.

[0018] As used herein, the term "noribogaine" refers to the alkaloid noribogaine including all enantiomers thereof. Of particular interest is the enantiomer depicted by the formula: where the configuration at the 2, 4, 5, 6 and 18 atoms are 2(R), 4(S), 5(S), 6(S) and 18(R).

[0019] The term "inert solid support" refers to a material having a rigid or semi-rigid surface which contains or can be derivatized to contain reactive functionality which covalently links noribogaine to the surface thereof through a cleavable linker. Such materials are well known in the art and include, by way of example, silica, synthetic silicates, biogenic silicates, porous glass, hydrogels, silicate-containing minerals, synthetic polymers, polystyrene, polypropylene, polyacrylamide, polyethylene glycol, polyacrylamide and copolymers thereof including copolymers of polystyrene/polyethylene glycol and polyacrylamide/polyethylene glycol, and the HO like. RECIEVED IPONZ 27 AUGUST 2010 6

[0020] As used herein, the terms "cleavable linking arms" or "cleavable linker" refer to linking arms, which are a chemical group or a covalent bond which covalently attaches at one end to a solid support and at the other end to noribogaine. At least one of the covalent bonds of the linking arm which attaches noribogaine to the solid support can be readily broken by specific chemical or enzymatic reactions, thereby providing for noribogaine free of the solid support. The chemical or enzymatic reactions employed to break the covalent bond of the linking arm are selected so as to be specific for bond breakage thereby preventing unintended reactions occurring elsewhere on the compound. The cleavable linking group is selected relative to noribogaine formed on the solid support so as to prevent premature cleavage of noribogaine from the solid support as well as not to interfere with any of the procedures employed during synthesis on the support. Suitable cleavable linking arms are well known in the art, and may include such groups as carbonate groups, carbamate groups, amide groups, and the like. In a preferred embodiment, the cleavable linker arm contains no more than 10 atoms. More preferably, the cleavable linker contains from 1 to 4 carbon atoms and from 2 to 4 heteroatoms selected from oxygen, nitrogen, sulfur, S(O) and S(0)2.

[0021] As used herein, the term "reaction conditions" refers to details under which a chemical reaction proceeds. Examples of reaction conditions include, but are not limited to, one or more of following: reaction temperature, solvent, pH, pressure, reaction time, mole ratio of reactants, the presence of a base or acid, or catalyst, etc. Reaction conditions may be named after the particular chemical reaction in which the conditions are employed, such as, decarboxylation conditions, olefin arylation conditions, anhydrous reaction conditions, etc. Reaction conditions for known reactions are generally known to those skilled in the art.

[0022] As used herein, the term "anhydrous reaction conditions" refers to reaction conditions wherein water is excluded. Such conditions are known to one of skill in the art, and typically comprise one or more of dry or distilled solvents and reagents, dried reaction vessels, the presence of a drying agent, such as activated molecular sieves, magnesium sulfate, sodium sulfate etc.

[0023] As used herein, the term "reducing agent" refers to a reagent which can donate electrons in an oxidation-reduction reaction, allowing hydrogen to be added to a molecule. RECIEVED IPONZ 27 AUGUST 2010 7 Suitable reducing agents include lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, and the like.

[0024] As used herein, the term "reductive amination conditions" refers to the reaction between an amine and a carbonyl compound to form an imine, which is subsequently reduced to an amine using a reducing agent. The intermediate imine can either be isolated and purified prior to the reducing step, or used in the reducing step without prior isolation or purification.

[0025] As used herein, the term "cyclization catalyst" refers to a catalyst which facilitates the cyclization between a cyclohex-2-enyl ester and an amine. Such catalysts include palladium catalysts such as Pd(PPh3)4.

[0026] As used herein, the term "olefin arylation conditions" refers to reaction conditions under which a covalent bond is formed between an olefin and an aryl or heteroaryl group. The reaction results in the overall reduction of the olefin and retention of the aromaticity of the aryl or heteroaryl group. Such reaction conditions include one or more catalysts such as (CH3CN)2PdCl2 and AgBF4.

[0027] As used herein, the term "decarboxylation conditions" refers to reaction conditions in which a carboxylic acid or an ester is replaced by hydrogen. Typically, decarboxylation reactions result in the release of carbon dioxide. In certain embodiments, the decarboxylation conditions first comprise hydrolysis of an ester to the corresponding carboxylic acid using e.g. sodium hydroxide. The decarboxylation can be accomplishing using standard decarboxylation reactions, such as the use of lead tetraacetate followed by hydride reduction of the resultant imine or under standard Barton reaction conditions. The decarboxylation reaction conditions can comprise heat and/or radical initiation. The art is replete with such procedures.

[0028] "Alkyl" refers to groups having from 1 to 6 carbon atoms and more preferably 1 to 3 carbon atoms. The alkyl group may contain linear or branched carbon chains. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, n-pentyl and the like. The term "Cx alkyl" refers to an alkyl group having x carbon atoms, wherein x is an integer, for example, C3 refers to an alkyl group having 3 carbon atoms. RECIEVED IPONZ 27 AUGUST 2010 8

[0029] "Aryl" refers to a monovalent aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) which condensed rings may or may not be aromatic (e.g., 2-benzoxazolinone, 2H-l,4-benzoxazin-3(4H)-one-7-yl, and the like) provided that the point of attachment is at an aromatic carbon atom.

[0030] "Cycloalkyl" refers to cyclic alkyl groups of from 3 to 10 carbon atoms having single or multiple cyclic rings including, by way of example, adamantyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl and the like.

[0031] "Heteroaryl" refers to an aromatic group of from 1 to 10 carbon atoms and 1 to 4 heteroatoms selected from the group consisting of oxygen, nitrogen, sulfur within the ring, wherein the nitrogen and/or sulfur atom(s) of the heteroaryl are optionally oxidized (e.g., N-oxide, -S(O)- or -S(0)2-). Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl) wherein the condensed rings may or may not be aromatic and/or contain a heteroatom provided that the point of attachment is through an atom of the aromatic heteroaryl group. Examples of heteroaryls include pyridyl, pyrrolyl, indolyl, thiophenyl, and furyl.

[0032] "Heterocycle" or "heterocyclic" or "heterocycloalkyl" or "heterocyclyl" refers to a saturated or partially saturated, but not aromatic, group having from 1 to 10 ring carbon atoms and from 1 to 4 ring heteroatoms selected from the group consisting of nitrogen, sulfur, or oxygen. Heterocycle encompasses single ring or multiple condensed rings, including fused bridged and spiro ring systems. In fused ring systems, one or more the rings can be cycloalkyl, aryl, or heteroaryl provided that the point of attachment is through the non-aromatic heterocyclic ring. In one embodiment, the nitrogen and/or sulfur atom(s) of the heterocyclic group are optionally oxidized to provide for the N-oxide, sulfinyl, and/or sulfonyl moieties.

[0033] Examples of heterocycles and heteroaryls include, but are not limited to, azetidine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, dihydroindole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, RECIEVED IPONZ 27 AUGUST 2010 9 phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydro-isoquinoline, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b]thiophene, morpholinyl, thiomorpholinyl (also referred to as thiamorpholinyl), piperidinyl, pyrrolidine, tetrahydrofuranyl, and the like.

[0034] As used herein, the term "optionally substituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group" refers to an alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group as defined herein optionally substituted with 1 to 3 substituents selected from the group consisting of alkyl, cycloalkyl, aryl, heterocycloalkyl, heteroaryl, halo, -OR10, -SR10, -CN, -N02, -C(0)R10, -C(0)0R10, -NR10R10, -S(0)R10, -S(0)2R10, -S(0)20R10, -S(O)NR10R10, -S(O)2NR10R10, -C(O)NR10R10, - NR10C(O)NR10R10, and -NR10C(S)NR10R10; and wherein R10 is independently hydrogen, alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl.

[0035] "Halo" or "halogen" refers to fluoro, chloro, bromo and iodo and preferably is fluoro or chloro.

[0036] "Carboxyl" refers to the group "-C(0)0H".

[0037] "Carboxyl ester" refers to the group "-C(0)0R9" where R9 is an optionally substituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group.

[0038] "Acyloxy" refers to the group "-0C(0)R9" where R9 is an optionally substituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group.

[0039] "Phosphate" refers to the groups -0P(0)(0H)2 (monophosphate), -0P(0)(0H)0P(0)(0H)2 (diphosphate) and -0P(0)(0H)0P(0)(0H)0P(0)(0H)2 (triphosphate) or salts thereof including partial salts thereof including partial salts thereof. The term "phosphate ester" includes esters of the mono-, di- and tri-phosphate groups described above wherein one or more hydrogen is replaced by an R9, where R9 is an optionally substituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group.

[0040] "Phosphonate" refers to the groups -P(0)(0H)2 (monophosphonate), -P(0)(0H)0P(0)(0H)2 (diphosphonate) and -P(0)(0H)0P(0)(0H)0P(0)(0H)2 (triphosphonate) or salts thereof including partial salts thereof including partial salts thereof. The term "phosphonate ester" includes esters of the mono-, di- and tri-phosphonate groups RECIEVED IPONZ 27 AUGUST 2010 10 described above wherein one or more hydrogen is replaced by an R9, where R9 is an optionally substituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group.

[0041] "Amide" refers to the groups -C(0)NH2, -C(0)NHR9 and -C(0)N(R9)2 where R9 is an optionally substituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group.

[0042] As used herein, the term "peptide" refers to a chain of from 1 to 5 a-amino acids linked by amide bonds (i.e. -NH-C(O)-). The amino acids can be naturally occurring or synthetic amino acids.

[0043] As used herein, the term "peptidomimetic" refers to a peptide-like chain designed to mimic a peptide. Peptidomimetics as used herein can include one or more amino acid mimetics, such as, but are not limited to, p-2- and p-3-amino acids, p-2.2-p-2.3. and P-3,3-disubstituted amino acids, a,a-disubstituted amino acids, D-amino acids, optionally substituted a-hydroxyacids, optionally substituted P-hydroxyacids, a-aminonitriles, N-alkylamino acids, and the like. In addition, the C-terminus of the peptidomimetic might be carboxylic acid or carboxamide, or other functional group resulting from the incorporation of one of the above mentioned amino acid mimetics.

[0044] As used herein, the term "biodegradable, biocompatible polymer" refers to a polymer which degrades in the body and does not itself or the degradation products thereof produce unacceptable toxicity or injurious side-effects on the biological systems of the mammal. A variety of natural and synthetic polymers have been explored for the preparation of nanoparticles, of which poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and their copolymers (PLGA) have been extensively investigated because of their biocompatibility and biodegradability. Suitable biodegradable polymers for preparing a nanoparticle of the invention include, but are not limited to, poly(lactide-co-glycolides), poly(lactic acid), poly(alkylene glycol), poly(butyl)cyanoacrylate, poly(methylmethacrylate-co-methacrylic acid), poly-allylamine, polyanhydride, polyhydroxybutyric acid, or polyorthoesters and the like.

[0045] As used herein, the term "chiral directing group" refers to an optically active chemical moiety that is incorporated into the compound so that a chemical transformation can be carried out stereoselectively to yield the desired product having at least 95% of the desired configuration. Typically, chiral directing groups are removed and are not a part of the desired RECIEVED IPONZ 27 AUGUST 2010 11 final product. The chiral directing group can have more than one chiral center. Suitable chiral directing groups can be derived from, in particular, alcohols, a- or P-amino acids, carboxylic groups such as optionally substituted alkyl (e.g., methyl, iso-propyl, tert-butyl), aryl (e.g., phenyl, biphenyl, 2,6-dimethylphenyl), heteroaryl (e.g., pyridinyl, oxazolyl, etc.), R22 and R23 are selected from hydrogen and groups such as optionally substituted alkyl (e.g., methyl, iso-propyl, tert-butyl), aryl (e.g., phenyl, biphenyl, 2,6-dimethylphenyl), heteroaryl (e.g., pyridinyl, 20 21 20 23 oxazolyl, etc.), or two of R and R or R and R together with the atom to which they are attached form an optionally substituted cycloalkyl or heterocycloalkyl ring, and further wherein R20, R21 and R22 are different.

[0046] As used herein, the term "palladium reactive functional group" refers to functional groups which can either directly react with palladium, or a precursor to such a group, such that the functional group reacts with a cyclization catalyst under cyclization conditions. Suitable groups include, but are not limited to, acyloxy, hydroxyl, phosphate, phosphate ester, -0S(0)20H, -0S(0)20R9 where R9 is optionally substituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl, or -OR8 where R8 is a hydroxyl protecting group.

[0047] As used herein, the term "pharmaceutic ally acceptable salt" refers to pharmaceutic ally acceptable salts of a compound of Formula I which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

[0048] As used herein, the term "protecting group" or "Pg" refers to well known functional groups which, when bound to a functional group, render the resulting protected functional group acids, and the like. Exemplary groups are shown below, where R20 and R21 are selected from RECIEVED IPONZ 27 AUGUST 2010 12 inert to the reaction conditions to be conducted on other portions of the compound and which, at the appropriate time, can be reacted to regenerate the original functionality under "deprotection conditions". The identity of the protecting group is not critical and is selected to be compatible with the remainder of the molecule. In one embodiment, the protecting group is an "amino protecting group" which protects the amino functionality of ibogaine or noribogaine during the reactions described herein. Examples of conventional amino protecting groups include, for instance, benzyl, acetyl, oxyacetyl, carboxybenzyl (Cbz), and the like. In another embodiment, the protecting group is a "hydroxy protecting group" which protects the hydroxyl functionality of noribogaine. Examples of hydroxyl protecting groups include, for instance, benzyl, p-methoxybenzyl, p-nitrobenzyl, allyl, trityl, dialkylsilylethers, such as dimethylsilyl ether, and trialkylsilyl ethers such as trimethylsilyl ether, triethylsilyl ether, and t-butyldimethylsilyl ether; esters such as benzoyl, acetyl, phenylacetyl, formyl, mono-, di-, and trihaloacetyl such as chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl; and carbonates such as methyl, ethyl, 2,2,2-trichloroethyl, allyl, benzyl, and p-nitrophenyl. Additional examples of hydroxy protecting groups may be found in standard reference works such as Greene and Wuts, Protective Groups in Organic Synthesis., 2d Ed., 1991, John Wiley & Sons, and McOmie Protective Groups in Organic Chemistry, 1975, Plenum Press. Methods for protecting and deprotecting the phenolic hydroxyl group of the compounds disclosed herein can be found in the art, and specifically in Greene and Wuts, supra, and the references cited therein. Preparation of Noribogaine

[0049] Noribogaine compositions of this invention can be prepared from ibogaine or by synthesis of noribogaine by chiral directed synthetic routes. In the former case, noribogaine containing less than 100 ppm ibogaine can be prepared using solid support synthesis as described below. As this compound is prepared from the natural product ibogaine and since the reactions described below do not involve any of the stereochemical centers, noribogaine so prepared will be least 95% of the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and likely to be 100% of that enantiomer. RECIEVED IPONZ 27 AUGUST 2010 13

[0050] In the case of solid support synthesis of noribogaine, the noribogaine compositions of this invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

[0051] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Fourth Edition, Wiley, N.Y., 2007, and references cited therein.

[0052] Furthermore, the compounds of this invention contain multiple chiral centers and the desired noribogaine enantiomer is the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer.

[0053] It is contemplated that noribogaine can be prepared and/or purified from ibogaine by utilizing solid support as shown in the following Schemes, where PG represents an amine protecting group, LG represents a leaving group (e.g. a halo or alcohol), L represents a cleavable linking group (e.g. a carbonyl compound such as a carbonate or carbamate) and the shaded circle represents a solid support.

[0054] In the following Schemes, the O-demethylation of the aryl methoxy group to yield the corresponding phenol can be accomplishing using any suitable method known in the art. Suitable reagents include a Lewis acid (e.g. BBr3, AICI3), a nucleophile (e.g. RS-, N3-, SCN-), NaCN at low pH (e.g. pH 12), and the like. In some embodiments, the O-demethylation should be performed without affecting the linkage to the solid support or altering the stereochemistry of the stereochemical centers on the molecule. Suitable reagents can be readily ascertained by one of skill in the art and can be found, for example, in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Fourth Edition, Wiley, N.Y., 2007 (see, e.g., the reactivity charts at pages 1006-1008 and 1022-1032), and references cited therein. RECIEVED IPONZ 27 AUGUST 2010

[0055] Noribogaine 5 can be prepared and purified from ibogaine 10 by any one of the routes shown in Scheme 1. Noribogaine, compound 5, is differentiated from ibogaine by virtue of the fact that the methoxy group of ibogaine has been converted to a hydroxyl group in noribogaine. In one embodiment, the indole amine of ibogaine can be protected using an amine protecting group to yield compound 1, followed by either tandem O-demethylation and removal of the protecting group using L-selectride®, for example, or sequential O-demethylation and removal of the protecting group to yield noribogaine 5. In addition, in one embodiment, noribogaine can be directly prepared and purified from the O-demethylation of ibogaine using methods known in the art and then purified by appending noribogaine to a solid support (compound 12 or 13), washing any contaminants, cleaving the linking group L, and recovering the noribogaine 5. In the above syntheses, one or more of the noribogaine or intermediates shown above can be purified using standard purification techniques known in the art (e.g. column chromatography, HPLC, and the like). Compounds of formula 11 are commercially available or can be synthesized in one or two steps from commercially available starting materials (see, e.g. commercially available resins from Sigma-Aldrich®). RECIEVED IPONZ 27 AUGUST 2010 15

[0056] In one embodiment, noribogaine can be prepared and purified from ibogaine in the manner described in Scheme 2 below: Scheme 2 support.

[0057] Specifically, in Scheme 2, amino protected ibogaine, compound 1, is contacted with boron tribromide or other conventional demethylating agent in e.g., methylene chloride using conditions well known in the art to yield the amino protected noribogaine, compound 2.

[0058] In Scheme 2, attachment of amino protected noribogaine, compound 2, to a solid support is accomplished by use of a chloroformate/solid support, compound 3, under conventional conditions to yield compound 4 wherein the carbonate group is shown for illustrative purposes only as the cleavable linking group. Other cleavable linkers can likewise be used in Scheme 2. As amino protected ibogaine does not contain a functional group reactive with compound 3, only amino protected noribogaine, compound 2, will react with the solid support and yield compound 4. Repeated washing of compound 4 will remove amino protected ibogaine contaminating the sample of amino protected noribogaine used in this reaction. Furthermore, at any time, a small portion of the solid support can be removed to provide a sample of noribogaine (after cleavage and deprotection). The sample can then be analyzed for RECIEVED IPONZ 27 AUGUST 2010 16 purity relative to any ibogaine present by conventional methods such as GC/MS, NMR, C13-NMR, etc.

[0059] Upon achieving the desired level of purity of noribogaine relative to any contaminating ibogaine, noribogaine, compound 5, can be recovered from the solid support by cleavage of the cleavable linker and subsequent deprotection of the amino group. Both cleavage and deprotection are well known in the art.

[0060] As desired, exceptionally pure noribogaine, compound 5, can be obtained by repeating the process of forming the amino protected noribogaine, compound 2, binding compound 2 to a solid support via the hydroxyl group of amino protected noribogaine and washing any contaminating ibogaine from the solid support. By repeating this process as often as necessary and preferably no more than 5 times, it is contemplated that noribogaine compositions having less than 100 ppm, or less than 50 ppm, or less than 1 ppm ibogaine and preferably less than 100 ppt ibogaine relative to the amount of noribogaine present in the composition can be prepared.

[0061] In one embodiment, the amount of ibogaine in a noribogaine composition can be determined by starting with a 14C enriched methoxy group on ibogaine. The amount of 14C over background in the final composition can be correlated to the amount of ibogaine in the noribogaine composition which can then be used to validate that the synthetic protocols employed are at or below the maximum amount of ibogaine permitted in the noribogaine composition. A 14C enriched methoxy group on ibogaine can readily be prepared by methylating the 12-hydroxyl group of noribogaine with an enriched 14C methylating agent. Techniques for determining the amount of a 14C in a composition are well known in the art and detection limits are below 1 ppt.

[0062] Alternatively, noribogaine can be prepared by total synthesis which ensures that ibogaine is not an intermediate during that synthesis. Such a synthetic protocol provides for noribogaine compositions having less than 100 ppm ibogaine and theoretically no ibogaine. The total synthesis is stereochemically directed such that the amount of the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer of noribogaine in the noribogaine composition is at least 95% of all of the noribogaine enantiomer s present, preferably at least 98% and more preferably at least 99%. In RECIEVED IPONZ 27 AUGUST 2010 17 one embodiment, the stereochemically directed synthesis of noribogaine 5 employs compound 21a in very high enantiomeric purity, 5 and is prepared by: a) contacting a compound of formula 21a with a compound of formula 21b, wherein X is a palladium reactive functional group or precursor thereof and R11 and R12 are hydrogen or a protecting group and wherein 21a is at least 95% the 1S,4S,6R configuration, 21a 21b under reductive amination reaction conditions to yield a compound of formula 21c: 21c b) contacting a compound of formula 21c with a cyclization catalyst under cyclizing conditions to yield a compound of formula 21d: RECIEVED IPONZ 27 AUGUST 2010 18 21d c) contacting a compound of formula 2Id under olefin arylation conditions to yield a compound of formula 21e: 21e; d) optionally contacting a compound of formula 21e under deprotection conditions to yield a compound of formula 5; and e) optionally converting compound of formula 5 to its pharmaceutic ally acceptable salt.

[0063] In the methods disclosed above, the indole nitrogen can be protected with an amino protecting group (R12) and deprotected as required using amine protecting groups as defined herein. The amino protecting group R12 can be the same as the hydroxyl protecting group R11 (e.g., optionally substituted benzyl) or can be an orthogonal protecting group.

[0064] In some embodiments, the reductive amination conditions comprise anhydrous reaction conditions. In some embodiments, the reductive amination conditions of step a) comprise magnesium sulfate. In some embodiments, step a) further comprises low temperatures (e.g. -10 to -5 °C).

[0065] In some embodiments, the reductive amination conditions of step a) comprises sodium borohydride (NaBH4). In some embodiments, the reductive amination conditions of step a) comprises sodium cyanoborohydride (NaBH3(CN)). In some embodiments, step a) further comprises raising the temperature when the reducing agent is added (e.g. 0 °C). RECIEVED IPONZ 27 AUGUST 2010 19

[0066] In some embodiments, the cyclization catalyst of step b) comprises Pd(PPh3)4. In some embodiments, Pd(PPh3)4 is added in an amount ranging from about 3% to about 6%. In some embodiments, step b) further comprises elevated temperatures (e.g. 70 °C).

[0067] In some embodiments, the olefin arylation conditions of step c) comprises (CH3CN)2PdCl2 and AgBF4. In some embodiments, step c) further comprises a base such as triethylamine. In some embodiments, step c) further comprises adding a reducing agent such as sodium borohydride (NaBH4). In some embodiments, step c) further comprises elevated temperatures (e.g. 70 °C).

[0068] In another of its method aspects, this invention is directed to a method for preparing noribogaine 5 from a compound of formula 22e as shown in Scheme 3. In Scheme 3, R' is selected from the group consisting of carboxyl, carboxyl ester, amide, phosphonate, phosphonate ester, a peptide, a peptidomimetic, a biodegradable, biocompatible polymer, and-C(0)R18 where R18 is -NH(CH2)nS(0)20H, -NH(CH2)nOH, -C(0)R19, -0C(0)R19, -CH2C(0)R19, or -CH2C(0)0R19 where R19 is optionally substituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl and n is 2-5, X is a palladium reactive functional group or precursor thereof (e.g., X can be acyloxy, hydroxyl, phosphate, phosphate ester, -0S(0)20H, -0S(0)20R19 where R19 is optionally substituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl, or -OR18 where R18 is a hydroxyl protecting group), R11 is hydrogen or a protecting group, and R12 is hydrogen or a protecting group. RECIEVED IPONZ 27 AUGUST 2010

[0069] As shown above in Scheme 3, amine 22c can be prepared by reacting 22a with 22b under anhydrous conditions in a suitable solvent, such as benzene, toluene, and the like, in the presence of a drying agent such as activated molecular sieves, magnesium sulfate, sodium sulfate etc. The reaction is preferably conducted at low temperature (i.e. -10 to -5 °C). The resultant imine can be used in the next step without purification or isolation. Amine 22c can be provided from the imine using a reducing agent, such as sodium borohyride at low temperature (i.e. 0 °C). Cyclization of amine 22c to yield compound 22d can proceed using a catalyst, such as Pd(PPh3)4. The cyclization reaction can be conducted in a polar solvent, such as acetonitrile, at elevated temperature (i.e. 70 °C). Compound 22d can be purified using standard purification methods (i.e. liquid chromatography). Compound 22e can be provided from compound 22d using a palladium-silver catalyzed olefin arylation reaction. Suitable reaction conditions can include (CH3CN)2PdCl2 and AgBF4 in the presence of triethylamine in acetonitrile at elevated temperature (e.g. 70 °C). A reducing agent such as sodium borohydride can be used to liberate the catalyst and yield compound 22e. Compound 22e can be purified using standard purification methods (i.e. liquid chromatography). It is contemplated that compound 22e can be further RECIEVED IPONZ 27 AUGUST 2010 21 purified using classical resolution (i.e. chromatography, crystallization, fractional crystallization, etc.) known in the art to provide substantially enantiomerically pure compound 22e.

[0070] Both enantiomers of compounds of formula 22b can be obtained from commercial sources (Aldrich®, USA) or prepared using methods known to one of skill in the art. In some embodiments, compound 22b is of the formula R12 wherein R11 and R12 are each independently hydrogen or a protecting group and R14 is optionally substituted alkyl or aryl. In certain embodiments, R14 is nitrobenzyl or bromobenzyl.

[0071] It is contemplated that either the S- or R-configuration of 22b can be used in Scheme 3, above, to afford the diastereomeric compounds R-22e and S-22e, shown below, wherein R11 and R14 are as described hereinabove. R-22e S-22e

[0072] Noribogaine can be prepared from compounds of formula 22e via decarboxylation and deprotection as shown in Scheme 4, below. In Scheme 4, R11 is a protecting group and R14 is an optionally substituted alkyl, cycloalkyl, aryl, heterocycloalkyl or heteroaryl group, and the indole nitrogen can optionally be protected using an amine protecting group as defined herein. The decarboxylation and deprotection steps can be performed simultaneously or sequentially. In addition, the ester can be hydrolyzed to the carboxylic acid prior to decarboxylation. RECIEVED IPONZ 27 AUGUST 2010 22g R11-0 22 Scheme 4 hydrolysis hydrolysis / ^decarboxylation deprotection R11-0 ov V-OR14 ry / *( N H 22e hydrolysis hydrolysis / decarboxylation deprotection decarboxylation deprotection deprotection 23 decarboxylation HQ cx N N^r H 5 decarboxylation O.

[0073] The methods disclosed herein provide for the synthesis of stereochemically enriched noribogaine having the 2R, 4S, 5S, 18R configuration. In some embodiments, the 2R, 4S, 5S, 18R noribogaine 5 is provided in at least about 95% the 2R, 4S, 5S, 18R configuration, or at least about 98% the 2R, 4S, 5S, 18R configuration, or at least about 99% the 2R, 4S, 5S, 18R configuration, or at least about 99.5% the 2R, 4S, 5S, 18R configuration.

[0074] In addition, this invention provides for novel intermediates as shown below. RECIEVED IPONZ 27 AUGUST 2010 23 Vt n\ \ / a Nn> \ / A N N N^r/'-r—\ N^r^~ H U--M H U--^A H U-- 3 S-3 R-3

[0075] In some embodiments, the methods disclosed herein further comprise the step of further separating two or more stereoisomers. Such methods for separating stereoisomers (including enantiomers and diastereomers) are known in the art and include chiral column chromatography, chiral resolving agents and the like.

[0076] The starting materials for the above reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wis., USA), Bachem (Torrance, Calif., USA), Emka-Chemce or Sigma (St. Louis, Mo., USA). Others may be prepared by procedures, or obvious modifications thereof, described RECIEVED IPONZ 27 AUGUST 2010 24 in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1 15 (John Wiley and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1 5 and Supplemental (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1 40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4.sup.th Edition), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).

[0077] It is contemplated that the (lS,4S,6R)-4-ethyl-6-formylcyclohex-2-enyl acetate 21a for use in the methods disclosed herein can be prepared in at least 95% the 1S,4S,6R configuration. However, it is preferred to have compound 21a in greater than 98%, or greater than 99%>, or about 99.5%, the 1S,4S,6R configuration.

[0078] Accordingly, it is contemplated that the (lS,4S,6R)-4-ethyl-6-formylcyclohex-2-enyl acetate 21a to be used in step a) can be prepared via an asymmetric Diels-Alder reaction. The asymmetric Diels-Alder can be performed using a chiral directing group on the diene (i.e., R10 is a chiral directing group as defined herein). Suitable chiral directing groups can be derived from, in particular, chiral alcohols, p-amino alcohols, a- or P-amino acids, and the like. Exemplary groups are shown below, where R20 and R21 are selected from groups such as optionally substituted alkyl (e.g., methyl, iso-propyl, tert-butyl), aryl (e.g., phenyl, biphenyl, 2,6-dimethylphenyl), heteroaryl (e.g., pyridinyl, oxazolyl, etc.), and R22 and R23 are selected from hydrogen and groups such as optionally substituted alkyl (e.g., methyl, iso-propyl, tert-butyl), aryl (e.g., phenyl, biphenyl, 2,6-dimethylphenyl), heteroaryl (e.g., pyridinyl, oxazolyl, etc.), or 20 21 20 23 two of R and R or R and R together with the atom to which they are attached form an 20 21 22 optionally substituted cycloalkyl or heterocycloalkyl ring, and further wherein R , R and R are different. O O O R10 A 21a RECIEVED IPONZ 27 AUGUST 2010 25 O O o O R20 H .OR23 R21 H NHR23

[0079] Typically, Diels-Alder reactions utilize a Lewis-acid catalyst. Suitable Lewis-acid catalysts are known in the art, and typically comprise aluminum, titanium, iron, ruthenium, boron, and the like. The Diels-Alder reaction is typically performed under anhydrous conditions which may include a drying agent, such as activated molecular sieves. In some embodiments, the Diels-Alder reaction is performed under pressure in a sealed vessel.

[0080] Still further, the asymmetric Diels-Alder reaction can be performed using a chiral Lewis-acid catalyst or a chiral organocatalyst known or prepared by one of skill in the art. Such chiral Lewis-acid catalysts are known in the art, and typically comprise aluminum, titanium, iron, ruthenium, boron, and the like (See, Corey, E.J. Angew. Chem. Int. Ed. 2002, 41, 1650-1667). Suitable chiral organocatalysts include derivatives of proline or a-amino acid derived imidazolidinones.

[0081] However, the precise identity of the chiral directing group or the chiral Lewis-acid is not critical to the present invention as such methods for performing asymmetric Diels-Alder reactions have become routine in the art.

[00821] The present invention is directed to the compounds and intermediates disclosed herein, including all possible stereoisomers of compounds of formula 21b, 21c, 21d, 21e, 22b, 22c, 22d, 22e, 22f, 22g, and 23. It is contemplated that the compounds of formula 21b, 21c, 21d, 21e, 22b, 22c, 22d, 22e, 22f, 22g, and 23 can be further purified to yield at least 90%, or at least 95%, or at least 98%, of single stereoisomer using chiral resolution methods, such as chiral chromatography and/or crystallization of the diastereomeric salt using a chiral acid, such as tartaric acid, mandelic acid, lactic acid, and the like. Such methods are routine in the art.

[0083] The synthetic noribogaine of the present invention is distinguished from plant derived noribogaine (i.e. noribogaine synthesized from naturally occurring ibogaine) by its 14C content. 14C has a half-life of about 5,730 years and is generated in the upper atmosphere as 14C02. The RECIEVED IPONZ 27 AUGUST 2010 26 amount of 14C02 present is approximately 1 ppt (parts per trillion) and, through photosynthesis, accumulates in plants resulting in a 14C content of plant material of approximately 1 ppt. Accordingly, plant derived noribogaine (i.e. noribogaine synthesized from naturally occurring ibogaine) is expected to have approximately 1 ppt 14C. Conversely, the noribogaine and intermediates disclosed herein are derived from fossil fuels, which due to 14C decay, would have a 14C content of less than 1 ppt, or less than 0.9 ppt 14C. Accordingly, provided herein is noribogaine having a 14C content of less than 1 ppt, or less than 0.9 ppt, or less than 0.8 ppt, or less than 0.7 ppt, or less than 0.6 ppt, or less than 0.5 ppt, or less than 0.4 ppt, or less than 0.3 ppt, or less than 0.2 ppt, or less than 0.1 ppt. The amount of 14C can be analyzed using methods well known in the art (i.e. radiocarbon analyses can be carried out according to the American Society for Testing Materials ASTM D6866 procedure (ASTM international, 100 Barr Harbon Drive, PO Box C700, West Conshohocken, PA 19428-2959)). Furthermore, provided is a method for distinguishing synthetic noribogaine from plant derived noribogaine based on the 14C content.

[0084] It will be apparent to those skilled in the art that many modifications of the above exemplifying methods, both to materials and methods, may be practiced without departing from the scope of the current invention.

[0085] The following synthetic and biological examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this invention. Unless otherwise stated, all temperatures are in degrees Celsius. Examples

[0086] In the examples below, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning. Example 1 - Synthesis and Purification of Noribogaine from Ibogaine

[0087] Example 1 illustrates one method for the synthesis and purification of noribogaine from ibogaine which method follows Scheme 5 below: RECIEVED IPONZ 27 AUGUST 2010

[0088] Specifically, in Scheme 5, ibogaine is contacted with a stoichiometric excess of benzyl chloroformate in an inert solvent such as methylene chloride. The reaction mixture further contains at least a stoichiometric equivalent of diisopropylethylamine relative to ibogaine so as to scavenge the acid generated during the reaction. The reaction is maintained at room temperature under an inert atmosphere until the reaction is substantially complete as evidenced by, for example, thin layer chromatograpy. At which time, an O-demethylation reagent (e.g. boron tribromide or aluminum trichloride), or preferably a stoichiometric excess thereof, is added to the reaction mixture which is then maintained under conditions (e.g. room temperature) wherein the methoxy group of ibogaine has been converted to the hydroxyl group of noribogaine.

[0089] The hydroxyl group generated above is then employed as a complementary functionality for attachment of a solid support. In particular, an excess of chloroformate bound to a solid support is combined with N-CBZ-noribogaine under conventional conditions wherein a cleavable carbonate bond is formed. Chloroformate bound to a solid support can be prepared from a hydroxy-bearing polymer support (e.g. hydroxymethyl)polystyrene or polymer-bound benzyl alcohol, both commercially available from Sigma-Aldrich®) and carbonyl dichloride. As </div>

Claims

<div class="application article clearfix printTableText" id="claims"> RECIEVED IPONZ 27 AUGUST 2010 28 CBZ-ibogaine does not readily react under these O-demethylation conditions, it will remain in the solution phase of the reaction mixture and can be washed from the reaction mixture by conventional techniques including placing the solid support into a column and passing excess solvent through the column. [0090] In one particular example, 1kg of solid support containing CBZ-noribogaine is loaded onto a column. The stopper of the column is partially opened so that a flow rate through the column of 0.5 liters per hour is maintained. Methylene chloride is continuously fed to the top of the column and recovered at the base of the column. The recovered methylene chloride is stripped to provide residual CBZ-ibogaine. The process is continued until the effluent from the column no longer contains CBZ-ibogaine. At which time, a portion of the solid support is loaded into a hydrogenation vessel together with methanol and a catalytic amount of palladium on carbon. Hydrogenation is continued under elevated pressure for approximately 5 hours. The reaction is then stopped and the methanol recovered and stripped, thus yielding noribogaine. Additional purification of noribogaine can be achieved by HPLC as desired. RECEIVED at IPONZ on 1 September 2010 29 WHAT IS CLAIMED IS:

1. A composition comprising noribogaine wherein at least 95% of the noribogaine is present as the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and further wherein said composition comprises less than 100 ppm ibogaine contamination relative to the total amount of noribogaine.

2. The composition of claim 1, wherein the amount of ibogaine contained in the noribogaine compositions is less than 50 ppm.

3. The composition of claim 2, wherein the amount of ibogaine contained in the noribogaine composition is less than 1 ppm.

4. The composition of claim 3, wherein the amount of ibogaine contained in the noribogaine composition is less than 100 ppt.

5. The composition of any one of claims 1 to 4, wherein at least 98% of the noribogaine is present as the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer.

6. A composition comprising noribogaine wherein at least 98% of the noribogaine is present as the 2(R), 4(S), 5(S), 6(S) and 18(R) enantiomer and further wherein said composition comprises less than 10 ppm ibogaine contamination relative to the total amount of noribogaine.

7. A composition comprising noribogaine wherein the noribogaine has a 14C content of less than 1 ppt.

8. A composition comprising noribogaine substantially as hereinbefore described with reference to example 1. </div>